44 results
ARS
2023 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 24
Annual report to shareholders
4:27pm
benefit program, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation … , and any response to government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect
8-K
EX-1.1
TARS
Tarsus Pharmaceuticals Inc
1 Mar 24
Tarsus Announces Proposed $100.0 Million Public Offering
5:26pm
or investigation before or brought by any Governmental Entity (including, without limitation, the U.S. Food and Drug Administration (the “FDA … , are not the subject of any inquiry or investigation by any Governmental Authority or data protection authority regarding any of the foregoing.
“Data
S-3ASR
EX-4.5
bxo1ekjm7 eke7c6rq5
29 Feb 24
Automatic shelf registration
4:32pm
8-K
EX-1.1
eplo dp3de8rhfimp4kx
2 Aug 23
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of
4:10pm
ARS
am31w58uxqe2hgc
26 Apr 23
Annual report to shareholders
4:08pm
8-K
EX-1.1
8rrgb29f3mfb86nh
3 May 22
Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock
8:34pm
S-3
EX-1.2
fhrf19ret 057nfht
1 Nov 21
Shelf registration
5:04pm